Halozyme to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Halozyme (NASDAQ: HALO) announced that Dr. Helen Torley, President and CEO, will present and hold investor meetings at three upcoming conferences: TD Cowen on March 3, 2026, Leerink on March 10, 2026, and The Citizens Life Sciences Conference on March 11, 2026.

Live audio webcasts will be available on the company investor relations website, with replays accessible for 90 days after each event.

SAN DIEGO, Feb. 25, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, is scheduled to present and host investor meetings at the following investor conferences:

Event:				TD Cowen 46th Annual Healthcare Conference
Format:				Fireside Chat and 1x1 Meetings
Presentation Date:				Tuesday, March 3, 2026
Presentation Time:				8:10am PT / 11:10am ET
Location:				Boston, MA
Event:				Leerink Partners Global Healthcare Conference
Format:				Fireside Chat and 1x1 Meetings
Presentation Date:				Tuesday, March 10, 2026
Presentation Time:				10:00am PT / 1:00pm ET
Location:   Event: Format:   Presentation Date: Presentation Time: Location:				Miami, FL   The Citizens Life Sciences Conference Fireside Chat and 1x1 Meetings Wednesday, March 11, 2026 8:20am PT / 11:20am ET Miami, FL

Live audio webcasts of the presentations will be available in the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference.

About Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE^® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE^® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V. and Skye Bioscience.

Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and the Surf Bio hyperconcentration technology. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at‑home and healthcare‑provider settings. The development of the Surf Bio polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly and argenx.

Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex^® and XYOSTED^®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.
For more information, visit www.halozyme.com and connect with us on LinkedIn.

Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com

Sydney Charlton
Teneo
917-972-8407
sydney.charlton@teneo.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-participate-in-upcoming-investor-conferences-302696455.html

SOURCE Halozyme Therapeutics, Inc.

FAQ

When will Halozyme (HALO) present at the TD Cowen 46th Annual Healthcare Conference?

Halozyme will present at TD Cowen on Tuesday, March 3, 2026 at 8:10am PT / 11:10am ET. According to the company, Dr. Helen Torley will host a fireside chat and one-on-one investor meetings in Boston, with a live audio webcast available online.

How can investors watch Halozyme's (HALO) March 10, 2026 Leerink presentation?

Investors can listen via a live audio webcast on the company's investor relations website. According to the company, the Leerink presentation is scheduled for Tuesday, March 10, 2026 at 10:00am PT / 1:00pm ET, with replays available for 90 days.

What format is Halozyme's (HALO) presentation at The Citizens Life Sciences Conference on March 11, 2026?

Halozyme will conduct a fireside chat plus one-on-one investor meetings. According to the company, the session is set for Wednesday, March 11, 2026 at 8:20am PT / 11:20am ET in Miami, with an audio webcast posted on its investor site.

Will Halozyme (HALO) make replays of the investor conference webcasts available and for how long?

Yes. According to the company, replays of the audio webcasts will be available for 90 days following each conference, accessible through the investor relations section of the company's website for on-demand listening.

Who from Halozyme (HALO) will be presenting at the March 2026 investor conferences?

Dr. Helen Torley, President and Chief Executive Officer, will present and host investor meetings at all scheduled March 2026 conferences. According to the company, she will participate in fireside chats and one-on-one meetings at each event.

Where will Halozyme's (HALO) March 3, 10 and 11, 2026 presentations be held?

The events are in Boston, Miami, and Miami respectively: TD Cowen in Boston on March 3, Leerink in Miami on March 10, and The Citizens conference in Miami on March 11. According to the company, webcasts will be available online.